{
  "url": "https://www.fool.com/data-news/2025/08/07/prme-revenue-misses-by-73/",
  "authorsByline": "JesterAI",
  "articleId": "c6f0687b7a55481bb5b6195ae9a76b77",
  "source": {
    "domain": "fool.com",
    "location": {
      "country": "us",
      "state": "VA",
      "city": "Alexandria",
      "coordinates": {
        "lat": 38.8051095,
        "lon": -77.0470229
      }
    }
  },
  "imageUrl": "https://cdn.content.foolcdn.com/images/1umn9qeh/production/2e67fde4d458002cf59f26acf09dd58f97b62ce0-1024x1024.png",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-07T16:27:33+00:00",
  "addDate": "2025-08-07T16:38:16.533412+00:00",
  "refreshDate": "2025-08-07T16:38:16.533413+00:00",
  "score": 1.0,
  "title": "PRME Revenue Misses by 73%",
  "description": "PRME Revenue Misses by 73%",
  "content": "Prime Medicine (PRME -3.56%), a genetic medicine innovator developing next-generation gene editing therapies, released its second quarter 2025 earnings on August 7, 2025. The company reported GAAP revenue of $1.1 million, substantially below analyst estimates of $4.18 million and driven solely by collaboration revenue. Earnings per share (GAAP) came in at $(0.41). While the company reduced its net loss (GAAP) compared to Q2 2024, it continues to report persistent operating losses. This quarter stood out for major clinical progress in Prime Editing technology, a sharper pipeline focus, and a significant extension of cash reserves to fund operations into 2027. However, the shortfall in revenue (GAAP) and ongoing loss reflect continued challenges for pre-commercial genetic medicine companies.\n\nPrime Medicine is working to advance a new class of gene editing therapies. Its technology, Prime Editing, is designed to precisely repair disease-causing genetic mutations in human DNA without causing double-strand breaks. This approach enables more accurate and versatile correction, insertion, or deletion of DNA, potentially treating a wide range of genetic disorders. The company leverages partnerships and internal research to push its therapies through the clinic.\n\nRecently, Prime Medicine has tightened its focus around a few key clinical programs. Its strategy centers on progressing its internal pipeline in liver diseases such as Wilson\u2019s Disease and Alpha-1 Antitrypsin Deficiency, and cystic fibrosis (CF), while continuing collaborations with major partners like Bristol Myers Squibb (NYSE:BMY). The company\u2019s key success factors include advancing clinical milestones, managing research costs, and securing external funding to keep its high-cost development programs moving forward.\n\nMajor Developments and Financial Results for the Quarter\n\nPrime Medicine recorded its first-ever collaboration revenue (GAAP), as it recognized $1.1 million in collaboration revenue from a related party. This figure (GAAP revenue) was far below the analyst consensus, falling short by $3.06 million or about 73% under estimates (GAAP).\n\nOn the expense side, research and development spending (GAAP) decreased to $41.4 million from $43.1 million compared to Q2 2024. Prime Medicine attributed this reduction to a strategic pivot toward high-priority programs in the liver and lung, a scaling back of work on chronic granulomatous disease (CGD), and a cutback in R&D staffing after a recent restructuring. General and administrative costs increased modestly to $13.1 million, with the rise mainly due to severance payments and legal fees tied to the restructuring effort.\n\nOne of the most significant milestones was the announcement of initial clinical proof-of-concept data for Prime Editing in CGD. In its first clinical trial patient, the company observed rapid engraftment and restoration of a key enzyme function well above the clinical benefit threshold. Inflammatory markers for CGD also improved, returning to normal just 45 days after baseline. Fecal calprotectin (a measure of intestinal inflammation) dropped from 15 times the upper limit of normal at baseline to normal levels by Day 45. However, Prime Medicine stated it will not advance this CGD program further on its own and is seeking a partner or out-licensing opportunity to continue development.\n\nPrime Medicine secured up to $24 million in new funding from the Cystic Fibrosis Foundation, with $6.0 million already received for work targeting the G542X mutation in CF. This external funding both supports ongoing development and offers a third-party endorsement for the company\u2019s Prime Editing platform. Its ongoing collaboration with Bristol Myers Squibb continues, targeting ex vivo T-cell therapies for blood cancers and immune conditions.\n\nLooking Ahead: Financial Outlook and Key Watch Areas\n\nPrime Medicine extended its cash runway with a major equity raise of $144.2 million that closed after the quarter, which, combined with new foundation funding, brings pro-forma cash reserves to $259.6 million as of June 30, 2025. The company expects available cash to fund operations and capital spending into 2027, based on its pro-forma cash, cash equivalents, and investments. Strategic restructuring is expected to reduce cash requirements by almost half through 2027, reflecting a tighter spending profile post-workforce reduction.\n\nManagement did not provide detailed forward guidance on revenue or earnings for upcoming periods. Investors will likely monitor the pace of development for Wilson\u2019s Disease, Alpha-1 Antitrypsin Deficiency, and cystic fibrosis programs, including the expected delivery of initial clinical data for both liver disease programs in 2027 as guided by management. As the company relies on milestone and collaboration revenue, and timelines for internal programs are extended, volatility in quarterly financials and partnership execution will remain important watch points.\n\nPRME does not currently pay a dividend.\n\nRevenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.",
  "medium": "Article",
  "links": [
    "https://www.fool.com/quote/nasdaq/prme/"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "GAAP revenue",
      "weight": 0.07794358
    },
    {
      "name": "Prime Medicine",
      "weight": 0.07762768
    },
    {
      "name": "collaboration revenue",
      "weight": 0.07155983
    },
    {
      "name": "Prime Editing",
      "weight": 0.06985804
    },
    {
      "name": "pro-forma cash reserves",
      "weight": 0.0684427
    },
    {
      "name": "Prime Editing technology",
      "weight": 0.068115726
    },
    {
      "name": "pre-commercial genetic medicine companies",
      "weight": 0.06782688
    },
    {
      "name": "internal programs",
      "weight": 0.06520834
    },
    {
      "name": "PRME Revenue",
      "weight": 0.06417504
    },
    {
      "name": "initial clinical data",
      "weight": 0.06309636
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.97802734375
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.96240234375
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.9462890625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.93115234375
    }
  ],
  "sentiment": {
    "positive": 0.03390503,
    "negative": 0.8745117,
    "neutral": 0.091430664
  },
  "summary": "Prime Medicine (PRME) is developing next-generation gene editing therapies, with its Q2 2025 earnings falling by 73% below analyst estimates. The company reported GAAP revenue of $1.1 million, largely due to collaboration revenue, but continued to report persistent operating losses. Major clinical progress in Prime Editing technology, a sharper pipeline focus, and a significant extension of cash reserves to fund operations into 2027. Despite this, the shortfall in revenue (GAAP) and ongoing loss reflect challenges for pre-commercial genetic medicine companies. Prime Medicine's technology, Prime Editing, is designed to precisely repair disease-causing genetic mutations in human DNA without causing double-strand breaks and potentially treat a wide range of genetic disorders. The firm's focus is on progressing its internal pipeline in liver diseases, Alpha-1 Antitrypsin Deficiency, cystic fibrosis, and ongoing collaborations with major partners like Bristol Myers Squibb. Prime Medical secured up to $24 million in new funding from the Cystic Fibrosis Foundation, with $6.0 million already received for work targeting the G542X mutation in CF.",
  "shortSummary": "Prime Medicine's Q2 2025 earnings missed by 73% due to collaboration revenue, despite significant clinical progress and a significant cash injection, with future growth expected.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "1b93de6c4cf9422fad0ce13952af08df",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://www.fool.com/quote/nasdaq/prme/",
      "text": "Prime Medicine (NASDAQ: PRME)\n$3.88\n(-4.5%)\n-$0.18\nPrice as of August 7, 2025, 1:09 p.m. ET\nPrime Medicine Return vs. S&P\n| 1 Year | 5 Year | 5 Year Annualized | Since IPO |\n|---|\nPrime Medicine Company Info\nPrime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.\nNews & Analysis\nFeatured Article\nPRME Revenue Misses by 73%\nJesterAI | Aug 7, 2025\nFeatured Article\nWhy Prime Medicine Stock Was Climbing Higher This Week\nEric Volkman | Mar 20, 2025\nWhy Prime Medicine Stock Is Soaring Today\nJohnny Rice | Mar 19, 2025\nWhy Prime Medicine Stock Soared Nearly 12% Higher on Monday\nEric Volkman | Sep 30, 2024\nChanges are afoot at the company, and investors welcomed them.\n2 Growth Stocks That Could Make You Richer\nGeorge Budwell | Aug 28, 2024\nDiscover two cutting-edge growth stocks that could revolutionize medicine and space exploration.\n2 Magnificent Growth Stocks With Room to Run\nGeorge Budwell | Mar 27, 2024\nThese deeply undervalued growth stocks could be big winners for patient shareholders.\nBetter Growth Stock: Archer Aviation or Prime Medicine?\nGeorge Budwell | Dec 19, 2023\nWhich of these innovation-themed growth stocks is the better buy?\n1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years\nGeorge Budwell | Nov 30, 2023\nThis gene-editing company could sport a best-in-class platform.\nValuation\nPremium Investing Services\nInvest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services."
    }
  ],
  "argos_summary": "Prime Medicine reported Q2 2025 GAAP revenue of $1.1 million, significantly below analyst expectations of $4.18 million, while also posting a GAAP loss of $(0.41) per share. Despite the revenue shortfall, the company made notable clinical advancements in its Prime Editing technology and secured up to $24 million in funding from the Cystic Fibrosis Foundation. Prime Medicine is focusing on key clinical programs for liver diseases and cystic fibrosis, while managing costs and extending its cash reserves to support operations through 2027.",
  "argos_id": "DXR1PJUZ8"
}